NLS Total Liab from 2010 to 2025
| NLSPW Stock | USD 0.01 0 37.50% |
Total Liabilities | First Reported 2010-12-31 | Previous Quarter 9.6 M | Current Value 6.6 M | Quarterly Volatility 1.8 M |
Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Interest Income of 681.3 K, Depreciation And Amortization of 9.8 K or Interest Expense of 124.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.
NLS | Total Liab |
Latest NLS Pharmaceutics' Total Liab Growth Pattern
Below is the plot of the Total Liab of NLS Pharmaceutics AG over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. NLS Pharmaceutics' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
NLS Total Liab Regression Statistics
| Arithmetic Mean | 9,012,375 | |
| Geometric Mean | 8,819,895 | |
| Coefficient Of Variation | 19.48 | |
| Mean Deviation | 1,424,609 | |
| Median | 10,005,622 | |
| Standard Deviation | 1,755,460 | |
| Sample Variance | 3.1T | |
| Range | 5.5M | |
| R-Value | (0.51) | |
| Mean Square Error | 2.4T | |
| R-Squared | 0.26 | |
| Significance | 0.04 | |
| Slope | (187,586) | |
| Total Sum of Squares | 46.2T |
NLS Total Liab History
About NLS Pharmaceutics Financial Statements
NLS Pharmaceutics investors use historical fundamental indicators, such as NLS Pharmaceutics' Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NLS Pharmaceutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 9.6 M | 6.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.